Inga Reynisdóttir

8.9k citations

25 papers · 2.8k indexed · 2 hit papers · h-index 15

Co-authors: Joan Massagué Mong‐Hong Lee Kornélia Polyák Antonio Iavarone Carol Prives Paula N. Friedman Jill Bargonetti Rósa B. Barkardóttir
Topics: RNA modifications and cancer (4 papers)Cancer-related Molecular Pathways (4 papers)BRCA gene mutations in cancer (3 papers)
Cited by: Oncology Molecular Biology Cancer Research
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Circulation
Partner nations: Iceland United States Finland

In The Last Decade

Inga Reynisdóttir

25 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.

1995 833 citations Inga Reynisdóttir, Kornélia Polyák et al. Genes & Development profile →
Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.

1995 751 citations Mong‐Hong Lee, Inga Reynisdóttir et al. Genes & Development profile →

Peers

Countries citing papers authored by Inga Reynisdóttir

Since Specialization

Citations

This map shows the geographic impact of Inga Reynisdóttir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inga Reynisdóttir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inga Reynisdóttir more than expected).

Fields of papers citing papers by Inga Reynisdóttir

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inga Reynisdóttir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inga Reynisdóttir. The network helps show where Inga Reynisdóttir may publish in the future.

Co-authorship network of co-authors of Inga Reynisdóttir

This figure shows the co-authorship network connecting the top 25 collaborators of Inga Reynisdóttir. A scholar is included among the top collaborators of Inga Reynisdóttir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inga Reynisdóttir. Inga Reynisdóttir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	High Atlastin 2-2 (ATL2-2) Expression Associates with Worse Prognosis in Estrogen-Receptor-Positive Breast Cancer 2023 ·Genes ·Inga Reynisdóttir,Aðalgeir Arason,(unknown),(unknown),Bylgja Hilmarsdóttir,Gunnhildur Ásta Traustadóttir,Oskar T. Johannsson,Bjarni A. Agnarsson,Rósa B. Barkardóttir	1
2	Hsa-miR-21-3p associates with breast cancer patient survival and targets genes in tumor suppressive pathways 2021 ·PLoS ONE ·(unknown),Hildur Knútsdóttir,Aðalgeir Arason,Bylgja Hilmarsdóttir,Oskar T. Johannsson,Bjarni A. Agnarsson,Rósa B. Barkardóttir,Inga Reynisdóttir	35
3	Abstract 3709: miR-21-3p: A potential oncomir in breast cancer 2020 ·Cancer Research ·(unknown),Aðalgeir Arason,Bjarni A. Agnarsson,Oskar T. Johannsson,Bylgja Hilmarsdóttir,Rósa B. Barkardóttir,Inga Reynisdóttir	1
4	High expression of the vacuole membrane protein 1 (VMP1) is a potential marker of poor prognosis in HER2 positive breast cancer 2019 ·PLoS ONE ·(unknown),Aðalgeir Arason,(unknown),(unknown),(unknown),(unknown),Óskar Þór Jóhannsson,Bjarni A. Agnarsson,Rósa B. Barkardóttir,Inga Reynisdóttir	11
5	Identification of anticancer agents based on the thieno[2,3-b]pyridine and 1H-pyrazole molecular scaffolds 2016 ·Bioorganic & Medicinal Chemistry ·Chatchakorn Eurtivong,Inga Reynisdóttir,(unknown),Daniel P. Furkert,Margaret A. Brimble,Jóhannes Reynisson	18
6	Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer 2014 ·Proceedings of the National Academy of Sciences ·Johanna I. Kiiski,Liisa M. Pelttari,Sofia Khan,(unknown),Inga Reynisdóttir,Steven N. Hart,Hermela Shimelis,(unknown),Anne Kallioniemi,Johanna Schleutker,Arto Leminen,Ralf Bützow,Carl Blomqvist,Rósa B. Barkardóttir,Fergus J. Couch,Kristiina Aittomäki,Heli Nevanlinna	122
7	Abstract 3461: Expression levels of TOX3 and the risk allele of the associated SNP rs3803662 predict adverse outcome for breast cancer patients. 2013 ·Cancer Research ·(unknown),Rósa B. Barkardóttir,Aðalgeir Arason,Haukur Gunnarsson,Laufey T. Ámundadóttir,Bjarni A. Agnarsson,Oskar T. Johannsson,Inga Reynisdóttir	1
8	The risk allele of SNP rs3803662 and the mRNA level of its closest genes TOX3 and LOC643714predict adverse outcome for breast cancer patients 2012 ·BMC Cancer ·(unknown),Rósa B. Barkardóttir,Aðalgeir Arason,Haukur Gunnarsson,Laufey T. Ámundadóttir,Bjarni A. Agnarsson,Oskar T. Johannsson,Inga Reynisdóttir	25
9	The effect of PLC-γ2 inhibitors on the growth of human tumour cells 2012 ·European Journal of Medicinal Chemistry ·(unknown),Inga Reynisdóttir,Jóhannes Reynisson	46
10	A genetic contribution to inflammatory bowel disease in Iceland: A genealogic approach 2004 ·Clinical Gastroenterology and Hepatology ·Inga Reynisdóttir,Daníel F. Guðbjartsson,Jóhann Heiðar Jóhannsson,(unknown),Kristleifur Kristjánsson,Hreinn Stefánsson,Jeffrey R. Gulcher,Sigurður Björnsson	12
11	Linkage of Osteoporosis to Chromosome 20p12 and Association to BMP2 2003 ·PLoS Biology ·Unnur Styrkársdóttir,Jean‐Baptiste Cazier,Augustine Kong,Óttar Rolfsson,Helene Larsen,(unknown),(unknown),Margrét Sigurðardóttir,Yu Z. Bagger,Claus Christiansen,Inga Reynisdóttir,Struan F.A. Grant,Kristján Jónasson,Michael L. Frigge,Jeffrey R. Gulcher,Gunnar Sigurðsson,Kāri Stefánsson	196
12	Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis 2003 ·Gastroenterology ·Ingvar Bjarnason,(unknown),Árni Jón Geirsson,G Sigthorsson,Inga Reynisdóttir,Daníel F. Guðbjartsson,(unknown),Roy Sherwood,Kristleifur Kristjánsson,Ólafur Kjartansson,Bjarni Þjóðleifsson	58
13	Subclinical intestinal inflammation: an inherited abnormality in Crohn’s disease relatives? 2003 ·Gastroenterology ·Bjarni Þjóðleifsson,G Sigthorsson,Nick Cariglia,Inga Reynisdóttir,Daníel F. Guðbjartsson,Kristleifur Kristjánsson,Jonathan B. Meddings,Vilmundur Guðnason,J. H. Wandall,Leif Percival Andersen,Roy Sherwood,Matthı́as Kjeld,Einar Oddsson,H Gudjónsson,Ingvar Bjarnason	132
14	The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. 1997 ·Genes & Development ·Inga Reynisdóttir,Joan Massagué	292
15	Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.breakdown → 1995 ·Genes & Development ·Mong‐Hong Lee,Inga Reynisdóttir,Joan Massagué	751
16	Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.breakdown → 1995 ·Genes & Development ·Inga Reynisdóttir,Kornélia Polyák,Antonio Iavarone,Joan Massagué	833
17	Unusual Properties of a Replication-Defective Mutant SV40 Large T Antigen 1993 ·Virology ·Heather E. Lorimer,Inga Reynisdóttir,Seth Ness,Carol Prives	5
18	Phosphorylation and active ATP hydrolysis are not required for SV40 T antigen hexamer formation. 1993 ·Journal of Biological Chemistry ·Inga Reynisdóttir,Heather E. Lorimer,Paula N. Friedman,(unknown),Carol Prives	17
19	Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. 1992 ·Genes & Development ·Jill Bargonetti,Inga Reynisdóttir,Paula N. Friedman,Carol Prives	201
20	Thermally inactivated simian virus 40 tsA58 mutant T antigen cannot initiate viral DNA replication in vitro 1990 ·Journal of Virology ·Inga Reynisdóttir,David R. O’Reilly,Lois K. Miller,Carol Prives	19

About Inga Reynisdóttir

Inga Reynisdóttir is a scholar working on Cancer Research, Molecular Biology and Oncology, having authored 25 papers that have together received 2.8k indexed citations. Recurring topics across this work include RNA modifications and cancer (4 papers), Cancer-related Molecular Pathways (4 papers) and BRCA gene mutations in cancer (3 papers). The work is most often cited by research in Oncology (1.5k citations), Molecular Biology (2.0k citations) and Cancer Research (342 citations). Inga Reynisdóttir has collaborated with scholars based in Iceland, United States and Finland. Frequent co-authors include Joan Massagué, Mong‐Hong Lee, Kornélia Polyák, Antonio Iavarone, Carol Prives, Paula N. Friedman, Jill Bargonetti, Rósa B. Barkardóttir, Jóhannes Reynisson and Daníel F. Guðbjartsson. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact